Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting

Author:

Seal Brian1,Sullivan Sean D2,Ramsey Scott3,Asche Carl V4,Shermock Kenneth M5,Sarma Syam6,Zagadailov Erin7,Farrelly Eileen7,Eaddy Michael7

Affiliation:

1. Bayer HealthCare Pharmaceuticals, 100 Bayer Boulevard Whippany, NJ 07981, USA

2. University of Washington, Department of Pharmacy, Box 357630 Seattle, WA 98195-7630, USA

3. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, PO Box 19024, Seattle, WA 98109-1024, USA

4. University of Illinois College of Medicine, 808 S Wood St, Chicago, IL 60612, USA

5. Johns Hopkins University, 600 N Wolfe St, Carnegie 180, Baltimore, MD 21287, USA

6. Independent Consultant, 7908 Kara Court, Greenbelt, MD 20770, USA

7. Xcenda, 4114 Woodlands Parkway, Ste 500, Palm Harbor, FL 34685, USA

Abstract

ABSTRACT  Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Methods: Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. Results: There were 211,440 encounters for PCa between January 2006 and December 2010 (88,151 inpatient and 123,289 outpatient). Average cost per inpatient stay was US$12,286 versus US$4364 per outpatient visit. Most common treatment during an inpatient stay and outpatient visit was surgery (57%) and radiation (76%), respectively. A total of 80% of outpatient visits and 69.9% inpatient stays were associated with a single treatment; remaining encounters were associated with ≥2 treatments. Conclusion: Costs are consistent with previous estimates; however, multimodal therapy is an emerging trend that may be related to greater costs in the future which may also be a challenge for hospital decision makers.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference17 articles.

1. American Cancer Society. Cancer Facts and Figures 2012. www.cancer.org/Research/CancerFactsFigures/index.

2. Cancer statistics, 2012

3. Howlader N, Noone AM, Krapcho M (Eds). SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, USA. http://seer.cancer.gov/csr/1975_2008/.

4. LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARS

5. National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology™. Prostate cancer, v3.2012. NCCN. www.nccn.org.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3